This page shows the latest Bristol Myers Squibb news and features for those working in and with pharma, biotech and healthcare.
Bristol Myers Squibb (BMS) and GentiBio have announced a multi-year partnership to develop new regulatory T-cell (Treg) therapies to re-establish immune tolerance and repair tissue in patients living
Bristol Myers Squibb (BMS) and 2seventy bio – a spin-out of bluebird bio – have announced positive phase 3 trial top-line results for Abecma (idecabtagene vicleucel) as a treatment for relapsed
The Committee for Medicinal Products for Human Use (CHMP) branch of the European Medicines Agency (EMA) has recommended approval of the fixed-dose of Bristol Myers Squibb’s (BMS) Opdualag – a
Bristol Myers Squibb (BMS) has launched the Disability Diversity in Clinical Trials (DDiCT) initiative to ensure equal access to clinical trials, ensuring all patient groups are ‘reflective of the real-world
Bristol Myers Squibb has announced that the National Institute of Health and Care Excellence (NICE) has recommended the combination of Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of
The National Institute for Health and Care Excellence (NICE) has recommended Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) to treat adult patients with muscle invasive urothelial carcinoma (MIUC).
More from news
Approximately 195 fully matching, plus 946 partially matching documents found.
Catherine Owen(pictured) is Senior Vice President of Major Markets at Bristol Myers Squibb.
Bristol Myers Squibb and bluebird bio’s idecabtagene vicleucel CAR-T therapy further emphasise this point.
and. CAR-T therapies. Gilead’s acquisition of Kite Pharma and Bristol-Myers Squibb’s acquisition of Juno Therapeutics, as well as the merger and acquisition agreements between Novartis/Spark and
Celgene, now a subsidiary of Bristol-Myers Squibb (BMS), recently built its second production plant in Couvet, followed by the construction of a third production site in Boudry (Neuchâtel), to produce
Eli Lilly, Bristol-Myers Squibb and Pfizer also have multiple development programmes that are paused or delayed.
More from intelligence
Approximately 4 fully matching, plus 49 partially matching documents found.
Anthony Mancini joins from Bristol-Myers Squibb. Biotech company Genmab has appointed Anthony Mancini (pictured above) as executive vice president and to the newly created position of chief operating officer. ... Most recently, he led Bristol-Myers
Gilead appoints Michael Quigley to lead research team. A former Bristol-Myers Squibb executive has jumped ship to Gilead, where he will head up the company’s research biology group.
Bristol-Myers Squibb.
The latest movers in pharma. Bristol-Myers Squibb. Bristol-Myers Squibb has announced changes to its leadership team, following the retirement of its current executive vice president of corporate affairs and
Roger Tomlins (pictured right), who joins Wilmington from Bristol-Myers Squibb, has worked in healthcare for over 16 years, in both the pharmaceutical industry and the NHS.
More from appointments
Approximately 10 fully matching, plus 105 partially matching documents found.
future. The session titled A Strategic Approach to Revolutionizing Digital Impact for Medical Affairs, presented by Luca Dezzani (Johnson &Johnson), Bora Erdemli (ZS Associates), Stacey Gorski (AstraZeneca), and Shaji Kalathil (Bristol ... Myers Squibb),
The Excellence in Healthcare Partnerships category for our work with Bristol Myers Squibb.Our team developed a Back-to-Work Guide in partnership with people who have directly experienced, and overcome,
In the Excellence in Healthcare Partnerships category, working with Bristol Myers Squibb, our team developed a Back-to-Work Guide in partnership with people who have directly experienced, and overcome, the
In contrast to many existing treatments for more difficult-to-control forms of psoriasis which are intravenous, TYK2 inhibitors– like Bristol Myers Squibb’s deucravacitinib (BMS-986165) –are being trialed as
In August, Bristol Myers Squibb announced it was committing $300m to tackle diversity in clinical trials, saying ‘COVID-19 has exposed the severity of social and health disparities in the US
More from PMHub
Approximately 3 fully matching, plus 11 partially matching documents found.
We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...